SEATTLE, May 3 Pacific Biomarkers, Inc. (OTC Bulletin Board: PBMC) ("PBI"), which provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research, today announced that it will introduce its new logo, branding strategy and marketing initiatives at two major biomarker industry conferences during the month of May 2010.
The Company will exhibit at the 2010 BIO International Convention in Chicago (May 3-6 2010) and at the Biomarker World Congress 2010 in Philadelphia (May 4-6, 2010).
"PBI is celebrating twenty years of providing high-quality esoteric assay services for clinical drug and diagnostic product development," stated Ron Helm, the Company's Chief Executive Officer. "Many of these assay services are encompassed by the term 'biomarker', which refers to any biological parameter that can be measured in patient samples and that provides specific information about the effects of a particular drug. Over the past five years, we have seen an accelerating trend towards the use of biomarkers in all phases of drug development, and many expect that this will lead to true personalized medicine. Therefore, our business strategy to focus on this type of testing is even more relevant today than it was when the Company was founded."
"We are also pleased to highlight that PBI is rolling out a new overall marketing look and logo along with our new name, Pacific Biomarkers, Inc. This marketing initiative is geared to further emphasize that PBI continues to aggressively expand its service offerings to include custom assay services for our pharmaceutical and biotechnology clients. In addition to our traditional biomarker services, we also provide assay development services for novel biomarkers, as well as custom assay services for immunogenicity testing, cell based assay and multiplex testing."
"We believe that our new name, Pacific Biomarkers, Inc., more accurately reflects both our current and historical strengths," continued Helm. "The term 'biomarker' is now much more widely known and is broadly understood to have a key role in drug development. Therefore, the new name accurately positions us as a specialty laboratory provider for contemporary drug development services."
The 2010 BIO International Convention, which will be held at McCormick Place in Chicago, is produced and hosted by the Biotechnology Industry Organization ("BIO"). It is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offering key networking and partnering opportunities, while providing insights and inspiration on major trends in the industry. Members of BIO, who are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products, range from entrepreneurial companies developing a first product to Fortune 500 multinationals. BIO also represents state and regional biotech associations, service providers to the industry, and academic centers. Additional information on the 2010 BIO International Convention is available on the Internet at www.convention.bio.org.
The Biomarker World Congress 2010, which will be held at the Loews Philadelphia Hotel, is the Cambridge Healthtech Institute's sixth annual signature conference dedicated to all aspects of biomarker research spanning the pharmaceutical and diagnostics pipeline. The meeting brings together a unique and international mix of large and medium-sized pharmaceutical, biotech and diagnostics companies, leading universities and research institutions, government and national laboratories, clinical research organizations, emerging companies and tool providers. The Congress also offers a balance of scientific sessions covering the latest research and scientific presentations, along with brainstorming sessions for decision makers. Additional information on the Biomarker World Congress 2010 is available on the Internet at www.biomarkerworldcongress.com.
About Pacific Biomarkers, Inc. (PBI)
Established in 1989, PBI provides biomarker laboratory services and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular and musculoskeletal diseases, diabetes, obesity, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing custom assays for novel clinical biomarkers, immunogenicity testing, cell-based assays, mass spectrometry, and multiplex testing.
PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol "PBMC". For more information about PBI, visit the company's web site at www.pacbio.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release includes forward-looking statements including, but not limited to, the following: results of business development activities; future growth; and the viability and acceptance of the Company's biomarker services. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, the following: the Company's ability to enter into contracts for its laboratory testing or biomarker services; client changes or early terminations of studies; variability in backlog; the success of marketing and business development efforts, and competitive factors; the Company's ability to manage growth; and other risks and uncertainties set forth in periodic filings with the U.S. Securities and Exchange Commission (including Form 10-K for the year ended June 30, 2009 and the subsequent 10-Q and 8-K filings).
For additional information, please contact: Ron Helm, CEO at (206) 298-0068 or RJ Falkner & Company, Inc., Investor Relations Counsel (800) 377-9893 [email protected]
SOURCE Pacific Biomarkers, Inc.